Episode 175 - March 6, 2026

The biotech sector's volatility and positive capital market developments are discussed, highlighting biotech's strong performance amid broader market uncertainties like the AI trade's controversies. Robust follow-on activity and IPOs in the biotech space are noted, with Q1 showing the strongest IPO activity in the past four years. The sentiment around biotech fundamentals is largely positive, with good investment appetite and enthusiasm despite market pullbacks. The conversation touches on the $2 billion settlement between Roivant and Moderna over lipid nanoparticle technology used in COVID vaccines, including potential implications for Pfizer. The impact of GLP-1 drugs on consumer behavior, such as reduced alcohol and soda consumption, and potential effects on sectors like casinos, are also examined.